Key result
Once-daily aspirin leaves ~33% of polycythemia vera patients with incomplete thromboxane inhibition.
Why the study?
Low-dose aspirin is recommended for patients with polycythemia vera to reduce thrombotic risk, but the extent of platelet thromboxane inhibition and optimal dosing regimen remain unclear.
Observational (n=49)
No
Answers are grounded in this paper and cite their sources.
May support twice-daily aspirin in polycythemia vera with high platelet counts; hypothesis-generating pending randomized outcome trials.
Low‐dose aspirin is currently recommended for patients with polycythemia vera (PV), a myeloproliferative neoplasm with increased risk of arterial and venous thromboses. Based on aspirin pharmacodynamics in essential thrombocythemia, a twice‐daily regimen is recommended for patients with PV deemed at particularly high thrombotic risk. We investigated the effects of low‐dose aspirin on platelet cyclooxygenase activity and in vivo platelet activation in 49 patients with PV, as assessed by serum thromboxane (TX) B2 and urinary TXA2/TXB2 metabolite (TXM) measurements, respectively. A previously described pharmacokinetic‐pharmacodynamic in silico model was used to simulate the degree of platelet TXA2 inhibition by once‐daily (q.d.) and twice‐daily (b.i.d.) aspirin, and to predict the effect of missing an aspirin dose during q.d. and b.i.d. regimens. Serum TXB2 averaged 8.2 (1.6–54.7) ng/ml and significantly correlated with the platelet count (γ = 0.39) and urinary TXM (γ = 0.52) in multivariable analysis. One‐third of aspirin‐treated patients with PV displayed less‐than‐maximal platelet TXB2 inhibition, and were characterized by significantly higher platelet counts and platelet‐count corrected serum TXB2 than those with adequate inhibition. Eight patients with PV were sampled again after 12 ± 4 months, and had reproducible serum TXB2 and urinary TXM values. The in silico model predicted complete inhibition of platelet‐derived TXB2 by b.i.d. aspirin, a prediction verified in a patient with PV with the highest TXB2 value while on aspirin q.d. and treated short‐term with a b.i.d. regimen. In conclusion, one in three patients with PV on low‐dose aspirin display less‐than‐maximal inhibition of platelet TXA2 production. Serum TXB2 measurement can be a valuable option to guide precision dosing of antiplatelet therapy in patients with PV.
No takes yet. Share an insight, caveat, or question.
Petrucci et al. (2022) conducted an observational in Polycythemia vera (n=49). Low-dose aspirin was evaluated on Median serum thromboxane B2 (TXB2) concentration 24 hours after dosing (ng/ml) (95% CI 1.6-54.7). One-third of patients with polycythemia vera receiving once-daily low-dose aspirin display less-than-maximal inhibition of platelet thromboxane production, which significantly correlates with higher platelet counts.
Synapse has enriched 10 related papers. Consider them for comparative context: